Dear Colleagues, As you may know, the FDA is considering regulating laboratory developed tests (LDTs) and had an open comment period that ended February 2, 2015.  We would like to share with you a response that we wrote from our perspective at PharmGKB, working with the Stanford Law School “IP

<!-- /* Font Definitions */ @font-face {font-family:"ＭＳ 明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"ＭＳ 明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:Calibri; panose-1:2 15 5 2

President Obama has requested that congress authorize $215 million dollars to fund the newly announced Precision Medicine Initiative. In addition to focusing on the development of cancer treatments tailored to individual cancers the initiative proposes to develop a research consortium to do a longitudinal cohort study of one million people.

"21st century businesses will rely on American science, technology, research and development. I want the country that eliminated polio and mapped the human genome to lead a new era of medicine — one that delivers the right treatment at the right time. In some patients with cystic fibrosis, this approach

Aloha! PharmGKB is at the Pacific Symposium on Biocomputing (PSB) on the big island of Hawaii. We will broadcast Phil Bourne's talk on "NIH Big Data from Science to Careers" over the web via the BlueJeans teleconferencing system. There will also be a phone number to